CAS: 425613-09-8

SJ000291942 is an activator of the canonical bone morphogenetic proteins (BMP) signaling pathway.

SJ000291942 is a drug that inhibits the growth of cancer cells in the laboratory. It has been shown to inhibit tumor formation and to prevent the development of metastases. SJ000291942 can be used to treat cancer by modulating neurological function, inhibiting cancer cell proliferation, and inducing apoptosis (programmed cell death). This drug binds to bone morphogenetic protein receptors and activates downstream signaling pathways that lead to cell death. SJ000291942 also has potent anti-inflammatory effects, as it decreases markers of inflammation such as IL-6, IL-1β, MMP-9, and TNF-α. It also increases markers of bone formation such as osteocalcin and osteoprotegerin.

SJ000291942